Stocks
Procter & Gamble Tipped as 37% Overvalued Amid New Clinical Product Launches
Procter & Gamble (PG) has seen two of its biggest personal care franchises enter clinical territory, launching Head & Shoulders HydraZinc Complex shampoos and expanding the premium Oral-B iO electric toothbrush range.
The product launches come after a muted stretch for Procter & Gamble, with the share price up 3.95% year to date but the 1-year total shareholder return fractionally down 0.46%.
According to Simply Wall St's valuation model, Procter & Gamble is significantly overvalued by 37%, trading at a fair value estimate of $107.52 versus its last close of $147.39.